Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas
Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gl...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Amin, Mohamadreza [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides - Nigolian, H. ELSEVIER, 2022, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:458 ; year:2013 ; number:2 ; day:31 ; month:12 ; pages:324-333 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijpharm.2013.10.018 |
|---|
| Katalog-ID: |
ELV021961913 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV021961913 | ||
| 003 | DE-627 | ||
| 005 | 20230625134543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2013.10.018 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013012000020.pica |
| 035 | |a (DE-627)ELV021961913 | ||
| 035 | |a (ELSEVIER)S0378-5173(13)00904-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.61 |2 bkl | ||
| 100 | 1 | |a Amin, Mohamadreza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. | ||
| 520 | |a Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. | ||
| 650 | 7 | |a Ethylenediaminetetraacetic acid (PubChem CID: 6049) |2 Elsevier | |
| 650 | 7 | |a Cholesterol (PubChem CID: 5997) |2 Elsevier | |
| 650 | 7 | |a Ammonium sulfate (PubChem CID: 6097028) |2 Elsevier | |
| 650 | 7 | |a α-Tocopherol (PubChem CID: 2116) |2 Elsevier | |
| 650 | 7 | |a Doxorubicin HCl (PubChem CID: 443939) |2 Elsevier | |
| 650 | 7 | |a Sodium azide (PubChem CID: 33557) |2 Elsevier | |
| 650 | 7 | |a HEPES (PubChem CID: 23831) |2 Elsevier | |
| 650 | 7 | |a Isopropanol (PubChem CID: 3776) |2 Elsevier | |
| 650 | 7 | |a Methylphenazonium methosulfate (PubChem CID: 9285) |2 Elsevier | |
| 650 | 7 | |a Hydroxylamine hydrochloride (PubChem CID: 443297) |2 Elsevier | |
| 700 | 1 | |a Badiee, Ali |4 oth | |
| 700 | 1 | |a Jaafari, Mahmoud Reza |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Nigolian, H. ELSEVIER |t Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |d 2022 |g New York, NY [u.a.] |w (DE-627)ELV008932840 |
| 773 | 1 | 8 | |g volume:458 |g year:2013 |g number:2 |g day:31 |g month:12 |g pages:324-333 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijpharm.2013.10.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.61 |j Innere Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 458 |j 2013 |e 2 |b 31 |c 1231 |h 324-333 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m a ma |
|---|---|
| matchkey_str |
aminmohamadrezabadieealijaafarimahmoudre:2013----:mrvmnopamckntcnattmrciiyfeyaelpsmloouiibtreigihmtyaeccird |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
44.61 |
| publishDate |
2013 |
| allfields |
10.1016/j.ijpharm.2013.10.018 doi GBVA2013012000020.pica (DE-627)ELV021961913 (ELSEVIER)S0378-5173(13)00904-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Amin, Mohamadreza verfasserin aut Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) Elsevier Badiee, Ali oth Jaafari, Mahmoud Reza oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:458 year:2013 number:2 day:31 month:12 pages:324-333 extent:10 https://doi.org/10.1016/j.ijpharm.2013.10.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 458 2013 2 31 1231 324-333 10 045F 610 |
| spelling |
10.1016/j.ijpharm.2013.10.018 doi GBVA2013012000020.pica (DE-627)ELV021961913 (ELSEVIER)S0378-5173(13)00904-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Amin, Mohamadreza verfasserin aut Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) Elsevier Badiee, Ali oth Jaafari, Mahmoud Reza oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:458 year:2013 number:2 day:31 month:12 pages:324-333 extent:10 https://doi.org/10.1016/j.ijpharm.2013.10.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 458 2013 2 31 1231 324-333 10 045F 610 |
| allfields_unstemmed |
10.1016/j.ijpharm.2013.10.018 doi GBVA2013012000020.pica (DE-627)ELV021961913 (ELSEVIER)S0378-5173(13)00904-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Amin, Mohamadreza verfasserin aut Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) Elsevier Badiee, Ali oth Jaafari, Mahmoud Reza oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:458 year:2013 number:2 day:31 month:12 pages:324-333 extent:10 https://doi.org/10.1016/j.ijpharm.2013.10.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 458 2013 2 31 1231 324-333 10 045F 610 |
| allfieldsGer |
10.1016/j.ijpharm.2013.10.018 doi GBVA2013012000020.pica (DE-627)ELV021961913 (ELSEVIER)S0378-5173(13)00904-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Amin, Mohamadreza verfasserin aut Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) Elsevier Badiee, Ali oth Jaafari, Mahmoud Reza oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:458 year:2013 number:2 day:31 month:12 pages:324-333 extent:10 https://doi.org/10.1016/j.ijpharm.2013.10.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 458 2013 2 31 1231 324-333 10 045F 610 |
| allfieldsSound |
10.1016/j.ijpharm.2013.10.018 doi GBVA2013012000020.pica (DE-627)ELV021961913 (ELSEVIER)S0378-5173(13)00904-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.61 bkl Amin, Mohamadreza verfasserin aut Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas 2013transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) Elsevier Badiee, Ali oth Jaafari, Mahmoud Reza oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:458 year:2013 number:2 day:31 month:12 pages:324-333 extent:10 https://doi.org/10.1016/j.ijpharm.2013.10.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 458 2013 2 31 1231 324-333 10 045F 610 |
| language |
English |
| source |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:458 year:2013 number:2 day:31 month:12 pages:324-333 extent:10 |
| sourceStr |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:458 year:2013 number:2 day:31 month:12 pages:324-333 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Innere Medizin |
| institution |
findex.gbv.de |
| topic_facet |
Ethylenediaminetetraacetic acid (PubChem CID: 6049) Cholesterol (PubChem CID: 5997) Ammonium sulfate (PubChem CID: 6097028) α-Tocopherol (PubChem CID: 2116) Doxorubicin HCl (PubChem CID: 443939) Sodium azide (PubChem CID: 33557) HEPES (PubChem CID: 23831) Isopropanol (PubChem CID: 3776) Methylphenazonium methosulfate (PubChem CID: 9285) Hydroxylamine hydrochloride (PubChem CID: 443297) |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| authorswithroles_txt_mv |
Amin, Mohamadreza @@aut@@ Badiee, Ali @@oth@@ Jaafari, Mahmoud Reza @@oth@@ |
| publishDateDaySort_date |
2013-01-31T00:00:00Z |
| hierarchy_top_id |
ELV008932840 |
| dewey-sort |
3610 |
| id |
ELV021961913 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021961913</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2013.10.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013012000020.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021961913</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(13)00904-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amin, Mohamadreza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ethylenediaminetetraacetic acid (PubChem CID: 6049)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cholesterol (PubChem CID: 5997)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ammonium sulfate (PubChem CID: 6097028)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">α-Tocopherol (PubChem CID: 2116)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Doxorubicin HCl (PubChem CID: 443939)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sodium azide (PubChem CID: 33557)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEPES (PubChem CID: 23831)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Isopropanol (PubChem CID: 3776)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Methylphenazonium methosulfate (PubChem CID: 9285)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hydroxylamine hydrochloride (PubChem CID: 443297)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Badiee, Ali</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jaafari, Mahmoud Reza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:458</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">day:31</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:324-333</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2013.10.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">458</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="b">31</subfield><subfield code="c">1231</subfield><subfield code="h">324-333</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Amin, Mohamadreza |
| spellingShingle |
Amin, Mohamadreza ddc 610 bkl 44.61 Elsevier Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas |
| authorStr |
Amin, Mohamadreza |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008932840 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.61 bkl Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) Elsevier |
| topic |
ddc 610 bkl 44.61 Elsevier Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) |
| topic_unstemmed |
ddc 610 bkl 44.61 Elsevier Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) |
| topic_browse |
ddc 610 bkl 44.61 Elsevier Ethylenediaminetetraacetic acid (PubChem CID: 6049) Elsevier Cholesterol (PubChem CID: 5997) Elsevier Ammonium sulfate (PubChem CID: 6097028) Elsevier α-Tocopherol (PubChem CID: 2116) Elsevier Doxorubicin HCl (PubChem CID: 443939) Elsevier Sodium azide (PubChem CID: 33557) Elsevier HEPES (PubChem CID: 23831) Elsevier Isopropanol (PubChem CID: 3776) Elsevier Methylphenazonium methosulfate (PubChem CID: 9285) Elsevier Hydroxylamine hydrochloride (PubChem CID: 443297) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a b ab m r j mr mrj |
| hierarchy_parent_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| hierarchy_parent_id |
ELV008932840 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008932840 |
| title |
Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas |
| ctrlnum |
(DE-627)ELV021961913 (ELSEVIER)S0378-5173(13)00904-6 |
| title_full |
Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas |
| author_sort |
Amin, Mohamadreza |
| journal |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| journalStr |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
324 |
| author_browse |
Amin, Mohamadreza |
| container_volume |
458 |
| physical |
10 |
| class |
610 610 DE-600 610 VZ 44.61 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Amin, Mohamadreza |
| doi_str_mv |
10.1016/j.ijpharm.2013.10.018 |
| dewey-full |
610 |
| title_sort |
improvement of pharmacokinetic and antitumor activity of pegylated liposomal doxorubicin by targeting with n-methylated cyclic rgd peptide in mice bearing c-26 colon carcinomas |
| title_auth |
Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas |
| abstract |
Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. |
| abstractGer |
Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. |
| abstract_unstemmed |
Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
2 |
| title_short |
Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas |
| url |
https://doi.org/10.1016/j.ijpharm.2013.10.018 |
| remote_bool |
true |
| author2 |
Badiee, Ali Jaafari, Mahmoud Reza |
| author2Str |
Badiee, Ali Jaafari, Mahmoud Reza |
| ppnlink |
ELV008932840 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.ijpharm.2013.10.018 |
| up_date |
2024-07-06T20:51:41.439Z |
| _version_ |
1803864350591549440 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021961913</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625134543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2013.10.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013012000020.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021961913</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(13)00904-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amin, Mohamadreza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Cyclic Arg-Gly-Asp (cRGD) pentapeptides engrafted liposomes have attracted considerable attention for targeting integrin receptors on tumor vasculature. In this study PEGylated liposomal doxorubicin (PLD) was decorated with three cRGD peptides including Arg-Gly-Asp-D-Tyr-Cys (RGDyC), Arg-Gly-Asp-D-Phe-Lys (RGDfK) and Arg-Gly-Asp-D-Phe-[N-Methyl]Lys (RGDf[N-Met]K). The in vitro liposome-cell-association and cytotoxicity experiments demonstrated the RGD-PLDs capability of internalization into integrin expressing HUVEC cells via receptor mediated endocytosis. The biodistribution studies revealed that decreasing the hydrophilicity of the peptide greatly reduces the RGD-PLDs blood clearance rate and increases their localization in C-26 colon carcinoma tumor model. Meanwhile, the most selective version, RGDf[N-Met]K, which has intermediate hydrophilicity revealed the lowest unwanted interactions with other integrin presenting sites, further localization in tumor, and lower doxorubicin (Dox) side effects. RGDf[N-Met]K-PLD demonstrated a superior control of tumor growth and increased the survival of mice. In this study, we introduced RGDf[N-Met]K for the first time, as a promising ligand for active targeting of liposomes to solid tumor which merits further investigations.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ethylenediaminetetraacetic acid (PubChem CID: 6049)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cholesterol (PubChem CID: 5997)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ammonium sulfate (PubChem CID: 6097028)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">α-Tocopherol (PubChem CID: 2116)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Doxorubicin HCl (PubChem CID: 443939)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sodium azide (PubChem CID: 33557)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEPES (PubChem CID: 23831)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Isopropanol (PubChem CID: 3776)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Methylphenazonium methosulfate (PubChem CID: 9285)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hydroxylamine hydrochloride (PubChem CID: 443297)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Badiee, Ali</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jaafari, Mahmoud Reza</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:458</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">day:31</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:324-333</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2013.10.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">458</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="b">31</subfield><subfield code="c">1231</subfield><subfield code="h">324-333</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3992596 |